Stock Analysis on Net

Danaher Corp. (NYSE:DHR)

$24.99

Analysis of Liquidity Ratios
Quarterly Data

Microsoft Excel

Paying user area


We accept:

Visa Mastercard American Express Maestro Discover JCB PayPal Google Pay
Visa Secure Mastercard Identity Check American Express SafeKey

Liquidity Ratios (Summary)

Danaher Corp., liquidity ratios (quarterly data)

Microsoft Excel
Dec 31, 2025 Sep 26, 2025 Jun 27, 2025 Mar 28, 2025 Dec 31, 2024 Sep 27, 2024 Jun 28, 2024 Mar 29, 2024 Dec 31, 2023 Sep 29, 2023 Jun 30, 2023 Mar 31, 2023 Dec 31, 2022 Sep 30, 2022 Jul 1, 2022 Apr 1, 2022
Current ratio
Quick ratio
Cash ratio

Based on: 10-K (reporting date: 2025-12-31), 10-Q (reporting date: 2025-09-26), 10-Q (reporting date: 2025-06-27), 10-Q (reporting date: 2025-03-28), 10-K (reporting date: 2024-12-31), 10-Q (reporting date: 2024-09-27), 10-Q (reporting date: 2024-06-28), 10-Q (reporting date: 2024-03-29), 10-K (reporting date: 2023-12-31), 10-Q (reporting date: 2023-09-29), 10-Q (reporting date: 2023-06-30), 10-Q (reporting date: 2023-03-31), 10-K (reporting date: 2022-12-31), 10-Q (reporting date: 2022-09-30), 10-Q (reporting date: 2022-07-01), 10-Q (reporting date: 2022-04-01).


The liquidity position, as indicated by the current, quick, and cash ratios, exhibits fluctuating trends over the observed period. Generally, liquidity strengthened through much of 2023 before experiencing a decline in late 2023 and early 2024, followed by a partial recovery towards the end of the period.

Current Ratio
The current ratio demonstrates an overall increasing trend from April 2022 to September 2023, rising from 1.68 to 2.26. A notable decrease is then observed in December 2023, falling to 1.68. Subsequent quarters show some volatility, with a low of 1.37 in September 2024, before recovering to 1.87 by December 2025. This suggests periods of improved short-term solvency followed by periods of potential strain, and then a recent strengthening.
Quick Ratio
Similar to the current ratio, the quick ratio generally improved from April 2022 to September 2023, increasing from 1.08 to 1.76. However, the decline in late 2023 is more pronounced, with the ratio dropping to 1.18 in December 2023. The quick ratio continues to decrease, reaching a low of 0.83 in December 2024, before showing improvement to 1.25 by December 2025. This indicates a weakening ability to meet short-term obligations with highly liquid assets, followed by a recovery.
Cash Ratio
The cash ratio exhibits the most significant fluctuations. It steadily increased from 0.49 in April 2022 to a peak of 1.31 in September 2023, indicating a substantial increase in the proportion of current assets held as cash. A sharp decline follows in December 2023, dropping to 0.71. The ratio then reaches its lowest point of 0.24 in September 2025, before recovering to 0.68 in December 2025. This suggests a shift in asset allocation, potentially involving investment of cash reserves, followed by a period of reduced cash holdings and a recent partial restoration.

The concurrent movements of these ratios suggest a coordinated liquidity management strategy. The increases in all three ratios through September 2023 indicate a strengthening of the short-term financial position. The subsequent declines, particularly in late 2023 and early 2024, warrant further investigation to understand the underlying causes, such as increased short-term liabilities or strategic asset deployment. The partial recovery observed in the later periods suggests a corrective response to these earlier trends.


Current Ratio

Danaher Corp., current ratio calculation (quarterly data)

Microsoft Excel
Dec 31, 2025 Sep 26, 2025 Jun 27, 2025 Mar 28, 2025 Dec 31, 2024 Sep 27, 2024 Jun 28, 2024 Mar 29, 2024 Dec 31, 2023 Sep 29, 2023 Jun 30, 2023 Mar 31, 2023 Dec 31, 2022 Sep 30, 2022 Jul 1, 2022 Apr 1, 2022
Selected Financial Data (US$ in millions)
Current assets
Current liabilities
Liquidity Ratio
Current ratio1
Benchmarks
Current Ratio, Competitors2
AbbVie Inc.
Amgen Inc.
Bristol-Myers Squibb Co.
Eli Lilly & Co.
Gilead Sciences Inc.
Johnson & Johnson
Merck & Co. Inc.
Pfizer Inc.
Regeneron Pharmaceuticals Inc.
Thermo Fisher Scientific Inc.
Vertex Pharmaceuticals Inc.

Based on: 10-K (reporting date: 2025-12-31), 10-Q (reporting date: 2025-09-26), 10-Q (reporting date: 2025-06-27), 10-Q (reporting date: 2025-03-28), 10-K (reporting date: 2024-12-31), 10-Q (reporting date: 2024-09-27), 10-Q (reporting date: 2024-06-28), 10-Q (reporting date: 2024-03-29), 10-K (reporting date: 2023-12-31), 10-Q (reporting date: 2023-09-29), 10-Q (reporting date: 2023-06-30), 10-Q (reporting date: 2023-03-31), 10-K (reporting date: 2022-12-31), 10-Q (reporting date: 2022-09-30), 10-Q (reporting date: 2022-07-01), 10-Q (reporting date: 2022-04-01).

1 Q4 2025 Calculation
Current ratio = Current assets ÷ Current liabilities
= ÷ =

2 Click competitor name to see calculations.


The current ratio exhibited a generally increasing trend from April 1, 2022, through September 26, 2025, with notable fluctuations. Initial values indicated a healthy liquidity position, which strengthened over the observed period before experiencing a decline and subsequent recovery.

Overall Trend
The current ratio began at 1.68 in April 2022 and generally increased, peaking at 2.26 in September 2023. A significant decrease was then observed in December 2023, falling to 1.68. The ratio then showed a recovery, reaching 1.87 by December 2025.
Period of Growth (Apr 1, 2022 – Sep 29, 2023)
From April 2022 to September 2023, the current ratio demonstrated consistent growth, increasing from 1.68 to 2.26. This suggests a strengthening liquidity position during this period, potentially due to effective working capital management or increased current asset levels relative to current liabilities. The most substantial increases occurred between July 1, 2022, and September 30, 2022 (0.07 increase) and between March 31, 2023, and September 29, 2023 (0.18 increase).
Period of Decline (Oct 1, 2023 – Mar 28, 2025)
A marked decline in the current ratio was observed from September 29, 2023, to March 28, 2025. The ratio decreased from 2.26 to 1.43, representing a substantial reduction in liquidity. This decrease could be attributed to a decrease in current assets, an increase in current liabilities, or a combination of both. The largest single decrease occurred between September 29, 2023, and December 31, 2023 (0.58 decrease).
Period of Recovery (Apr 1, 2025 – Dec 31, 2025)
Following the decline, the current ratio began to recover from April 1, 2025, reaching 1.87 by December 31, 2025. This indicates a potential stabilization or improvement in the short-term liquidity position. The recovery was gradual, with increases observed in subsequent quarters.
Recent Performance
The current ratio at the end of the observation period (December 31, 2025) stood at 1.87. While this represents an improvement from the low of 1.43 in March 2025, it remains below the peak of 2.26 observed in September 2023. This suggests that while liquidity has improved, there is still room for further strengthening.

Quick Ratio

Danaher Corp., quick ratio calculation (quarterly data)

Microsoft Excel
Dec 31, 2025 Sep 26, 2025 Jun 27, 2025 Mar 28, 2025 Dec 31, 2024 Sep 27, 2024 Jun 28, 2024 Mar 29, 2024 Dec 31, 2023 Sep 29, 2023 Jun 30, 2023 Mar 31, 2023 Dec 31, 2022 Sep 30, 2022 Jul 1, 2022 Apr 1, 2022
Selected Financial Data (US$ in millions)
Cash and equivalents
Trade accounts receivable, less allowance for doubtful accounts
Total quick assets
 
Current liabilities
Liquidity Ratio
Quick ratio1
Benchmarks
Quick Ratio, Competitors2
AbbVie Inc.
Amgen Inc.
Bristol-Myers Squibb Co.
Eli Lilly & Co.
Gilead Sciences Inc.
Johnson & Johnson
Merck & Co. Inc.
Pfizer Inc.
Regeneron Pharmaceuticals Inc.
Thermo Fisher Scientific Inc.
Vertex Pharmaceuticals Inc.

Based on: 10-K (reporting date: 2025-12-31), 10-Q (reporting date: 2025-09-26), 10-Q (reporting date: 2025-06-27), 10-Q (reporting date: 2025-03-28), 10-K (reporting date: 2024-12-31), 10-Q (reporting date: 2024-09-27), 10-Q (reporting date: 2024-06-28), 10-Q (reporting date: 2024-03-29), 10-K (reporting date: 2023-12-31), 10-Q (reporting date: 2023-09-29), 10-Q (reporting date: 2023-06-30), 10-Q (reporting date: 2023-03-31), 10-K (reporting date: 2022-12-31), 10-Q (reporting date: 2022-09-30), 10-Q (reporting date: 2022-07-01), 10-Q (reporting date: 2022-04-01).

1 Q4 2025 Calculation
Quick ratio = Total quick assets ÷ Current liabilities
= ÷ =

2 Click competitor name to see calculations.


The quick ratio exhibited a generally increasing trend from April 1, 2022, through September 26, 2025, followed by a notable increase in the final reporting period. However, there were periods of fluctuation, including a significant decline in the first half of 2024. The ratio consistently remained above 1.0 for the majority of the observed period, indicating a generally healthy short-term liquidity position.

Overall Trend
From April 1, 2022, to September 29, 2023, the quick ratio demonstrated a consistent upward trajectory, increasing from 1.08 to a peak of 1.76. This suggests an improving ability to meet short-term obligations with highly liquid assets. Following the peak, a decline was observed through June 28, 2024, reaching a low of 0.84. The ratio then recovered, reaching 1.25 by December 31, 2025.
Periods of Increase
The most substantial increases occurred between July 1, 2022, and December 31, 2022 (increasing from 1.13 to 1.30), and again between March 31, 2023, and September 29, 2023 (increasing from 1.34 to 1.76). These periods suggest successful management of current assets and liabilities, or potentially strategic shifts in working capital.
Periods of Decrease
A notable decrease occurred between September 29, 2023, and March 29, 2024, falling from 1.76 to 0.83. This decline continued through June 28, 2024, remaining at 0.84. This period warrants further investigation to understand the underlying causes, such as increased current liabilities or a reduction in quick assets. The subsequent recovery indicates corrective actions were taken or the decrease was temporary.
Recent Performance
The quick ratio experienced a significant increase in the final period, rising from 0.84 on September 26, 2025, to 1.25 on December 31, 2025. This suggests a strengthening of the short-term liquidity position at the end of the observation period.

The fluctuations in the quick ratio suggest a dynamic relationship between quick assets and current liabilities. While the ratio generally indicates a comfortable liquidity position, the periods of decline highlight the importance of ongoing monitoring and proactive management of working capital.


Cash Ratio

Danaher Corp., cash ratio calculation (quarterly data)

Microsoft Excel
Dec 31, 2025 Sep 26, 2025 Jun 27, 2025 Mar 28, 2025 Dec 31, 2024 Sep 27, 2024 Jun 28, 2024 Mar 29, 2024 Dec 31, 2023 Sep 29, 2023 Jun 30, 2023 Mar 31, 2023 Dec 31, 2022 Sep 30, 2022 Jul 1, 2022 Apr 1, 2022
Selected Financial Data (US$ in millions)
Cash and equivalents
Total cash assets
 
Current liabilities
Liquidity Ratio
Cash ratio1
Benchmarks
Cash Ratio, Competitors2
AbbVie Inc.
Amgen Inc.
Bristol-Myers Squibb Co.
Eli Lilly & Co.
Gilead Sciences Inc.
Johnson & Johnson
Merck & Co. Inc.
Pfizer Inc.
Regeneron Pharmaceuticals Inc.
Thermo Fisher Scientific Inc.
Vertex Pharmaceuticals Inc.

Based on: 10-K (reporting date: 2025-12-31), 10-Q (reporting date: 2025-09-26), 10-Q (reporting date: 2025-06-27), 10-Q (reporting date: 2025-03-28), 10-K (reporting date: 2024-12-31), 10-Q (reporting date: 2024-09-27), 10-Q (reporting date: 2024-06-28), 10-Q (reporting date: 2024-03-29), 10-K (reporting date: 2023-12-31), 10-Q (reporting date: 2023-09-29), 10-Q (reporting date: 2023-06-30), 10-Q (reporting date: 2023-03-31), 10-K (reporting date: 2022-12-31), 10-Q (reporting date: 2022-09-30), 10-Q (reporting date: 2022-07-01), 10-Q (reporting date: 2022-04-01).

1 Q4 2025 Calculation
Cash ratio = Total cash assets ÷ Current liabilities
= ÷ =

2 Click competitor name to see calculations.


The cash ratio exhibited considerable fluctuation throughout the observed period, spanning from April 1, 2022, to December 31, 2025. Initially, the ratio demonstrated an increasing trend, peaking in September 2023, before experiencing a substantial decline and subsequent partial recovery.

Initial Increase (Apr 1, 2022 – Sep 29, 2023)
From 0.49 in April 2022, the cash ratio generally increased, reaching a high of 1.31 in September 2023. This indicates a strengthening ability to cover current liabilities with immediately available cash during this timeframe. The increase correlates with a significant rise in total cash assets, which more than offset increases in current liabilities.
Significant Decline (Dec 31, 2023 – Jun 28, 2024)
A marked decrease in the cash ratio occurred between December 2023 and June 2024, falling from 0.71 to 0.35. This decline was primarily driven by a substantial reduction in total cash assets, while current liabilities remained relatively stable. This suggests a potential strain on the company’s immediate liquidity position.
Partial Recovery and Subsequent Fluctuation (Sep 27, 2024 – Dec 31, 2025)
Following the low in June 2024, the cash ratio experienced a modest recovery, reaching 0.68 by December 2025. However, this recovery was preceded by a further dip to 0.24 in September 2025. The fluctuations during this period suggest ongoing volatility in cash management or short-term financing strategies. The final value of 0.68 indicates an improved, but still variable, capacity to meet short-term obligations with cash.
Overall Trend
While the cash ratio demonstrated an initial positive trend, the latter portion of the period was characterized by significant volatility. The peak in September 2023 represents the strongest liquidity position observed, while the trough in June 2024 indicates the weakest. The final value suggests a return to a more moderate liquidity level, but continued monitoring is warranted given the recent fluctuations.

The observed changes in the cash ratio warrant further investigation into the underlying factors driving the fluctuations in both cash assets and current liabilities. Understanding these drivers is crucial for assessing the company’s ongoing liquidity risk and financial health.